A. Tatic

发表

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

A. Savic, H. Garelius, P. Fenaux, 2020, Haematologica.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2018, Leukemia.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2018, Leukemia research.

This is a repository copy of Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet

Saskia, Germing, A. Savic, 2018 .

The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis

D. Coriu, A. Lupu, S. Badelita, 2013 .

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

D. Swinkels, A. Stamatoullas, C. Craddock, 2020, Leukemia.

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2019, Haematologica.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

D. Swinkels, H. Garelius, E. Hellström-Lindberg, 2017, Haematologica.

Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.

D. Coriu, A. Crisan, A. Coliță, 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania.

D. Georgescu, R. Gologan, Didona Vasilache, 2009, Leukemia research.

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Alexandra G. Smith, D. Swinkels, H. Garelius, 2016 .

Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2016 .

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2019, Haematologica.

Programmed Cell Death Deregulation in BCR-ABL1-Negative Myeloproliferative Neoplasms

C. Diaconu, A. Neagu, L. Necula, 2019, Programmed Cell Death.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

A. Savic, P. Fenaux, E. Hellström-Lindberg, 2018, Blood advances.

Increased Dkk‐1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms

C. Tanase, C. Diaconu, Nicoleta P. Berbec, 2018, Journal of cellular and molecular medicine.

Case report: High-risk acute promyelocytic leukemia and COVID-19-related myocarditis one patient, two cytokine storms

M. Cirstea, D. Coriu, A. Ghiaur, 2023, Frontiers in Oncology.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

L. Saft, P. Fenaux, D. Mikulenková, 2017, Annals of Hematology.

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.

C. Pecquet, P. Saussoy, Olga Babosova, 2018, Blood.

Assessment of Total Antioxidant Capacity, 8-Hydroxy-2′-deoxy-guanosine, the Genetic Landscape, and Their Associations in BCR::ABL-1-Negative Chronic and Blast Phase Myeloproliferative Neoplasms

A. Botezatu, C. Diaconu, A. Neagu, 2024, International journal of molecular sciences.